Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT00104923Phase 1Completed

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Role: lead

NCT00467077Phase 2Terminated

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Role: lead

NCT00003843Terminated

Irinotecan in Treating Patients With Colorectal Cancer

Role: lead

NCT00387504Phase 1Completed

Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Role: lead

NCT00022607Phase 2Completed

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT00002980Phase 1Completed

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Role: lead

NCT00103103Phase 2Terminated

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

Role: lead

NCT00033410Phase 1Completed

Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Role: lead

All 8 trials loaded